AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Vaccine developer receives patent for delivery platform.
2003 NOV 5 - (NewsRx.com & NewsRx.net) -- BioVex Limited announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office in relation to one of its core patents.
The patent relates to the use of herpes simplex virus (HSV) as a platform for antigen delivery for vaccine purposes and covers both direct in vivo and ex vivo applications of the technology. The patent specifically relates to modified versions of HSV that allow high efficiency antigen delivery to dendritic cells combined with dendritic cell activation.
Considerable evidence from advanced clinical trials has shown that antigen presentation by the immune systems key policing cells - dendritic cells - can lead to a therapeutically effective immune response against disease associated antigens.
HSV infects and delivers antigen-encoding genes to dendritic cells at very high efficiency and has the potential to become the method of choice for antigen delivery to these cells. However, dendritic cells infected with HSV are usually in-activated by the infection process. BioVex has identified the HSV genes responsible for this inactivation. The deletion of these genes provides a proprietary vaccine platform which combines very efficient antigen delivery to, and optimal stimulation of, this key class of antigen presenting cell.
The company's lead product from ...
- BioVex's OncoVEX(GM-CSF) Clinical Trial Data to Be Featured by American...
- Newspaper article from: PR Newswire Europe April 19, 2005 700+ words
...oncolytic cancer vaccines OncoVEX(GM-CSF) is an oncolytic...metastatic tumour deposits. OncoVEX(GM-CSF) has completed...the administration of OncoVEX (GM-CSF) in either single...of immune policing (dendritic) cells. The Company's lead...
- BioVex Commences Phase 1 Clinical Trial With OncoVEX GM-CSF.
- Press release article from: PR Newswire June 24, 2002 700+ words
...application to commence a clinical trial of OncoVEX GM-CSF . The Phase I trial will be undertaken...The safety and biological activity of OncoVEX GM-CSF will be evaluated in a number of...provided by the oncolytic virus itself, OncoVEX GM-CSF carries the gene encoding human...
- BioVex Announces Preliminary Phase I Data on OncoVEX (Gm-Csf) in Patients With...
- Press release article from: PR Newswire January 6, 2003 700+ words
...oncology product candidate, OncoVEX (GM-CSF) in patients with breast cancer and melanoma. OncoVEX (GM-CSF) is the first oncolytic...cytokine gene GM-CSF. OncoVEX (GM-CSF) is currently undergoing...systems key policing cells -- dendritic cells -- can lead to a ...
- BioVex announces preliminary phase I data on OncoVEX GM-CSF patients with...
- Press release article from: PR Newswire January 6, 2003 700+ words
...product candidate, OncoVEX GM-CSF in patients with...cancer and melanoma. OncoVEX GM-CSF is the first...cytokine gene GM-CSF. OncoVEX GM-CSF is currently...key policing cells - dendritic cells - can lead to a therapeutically...
- BioVex to Present Updated Phase I Data on Oncovex GM-CSF in Patients With...
- Press release article from: PR Newswire May 30, 2003 700+ words
...oncology product candidate, OncoVEX GM-CSF, in patients with...between 9:00AM and 1:00PM. OncoVEX GM-CSF is the first oncolytic...from the administration of OncoVEX GM-CSF at single doses have...systems key policing cells - dendritic cells - can lead to an effective...
- BioVex to present updated Phase I data on OncoVEX GM-CSF in patients with...
- Press release article from: PR Newswire May 30, 2003 700+ words
...oncology product candidate, OncoVEX GM-CSF, in patients with...between 9:00AM and 1:00PM. OncoVEX GM-CSF is the first oncolytic...from the administration of OncoVEX GM-CSF at single doses have...systems key policing cells - dendritic cells - can lead to an effective...
- Biovex to Present OncoVEX GM-CSF and ImmunoVEX Data at the American Assocation...
- Press release article from: PR Newswire March 25, 2004 700+ words
...The Company's lead product, OncoVEX GM-CSF, is a new class of oncolytic...destroy metastatic deposits. OncoVEX GM-CSF is currently concluding...melanoma associated antigens to dendritic cells. In addition, the Company is...
- BioVex to Present Preliminary Phase I Data on Oncovex (GM-CSF) in Patients With...
- Press release article from: PR Newswire April 1, 2003 700+ words
...oncology product candidate, OncoVEX (GM-CSF) in patients with...systems key policing cells - dendritic cells - can lead to a therapeutically...antigen-encoding genes to dendritic cells at very high efficiency...these cells. However, dendritic cells infected with HSV are ...